

CORRIGENDA/ERRATUM

International uniform response criteria for multiple myeloma

BGM Durie¹, J-L Harousseau², JS Miguel³, J Bladé⁴, B Barlogie⁵, K Anderson⁶, M Gertz⁷, M Dimopoulos⁸, J Westin⁹, P Sonneveld¹⁰, H Ludwig¹¹, G Gahrton¹², M Beksac¹³, J Crowley¹⁴, A Belch¹⁵, M Boccardo¹⁶, I Turesson¹⁷, D Joshua¹⁸, D Vesole¹⁹, R Kyle⁷, R Alexanian²⁰, G Tricot⁵, M Attal²¹, G Merlini²², R Powles²³, P Richardson²⁴, K Shimizu²⁵, P Tosi²⁶, G Morgan²⁷ and SV Rajkumar⁷, on behalf of the International Myeloma Working Group²⁹

Leukemia (2007) 21, 1134. doi:10.1038/sj.leu.2404582

Correction to: *Leukemia* (2006) 20, 1467–1473. doi:10.1038/sj.leu.2404284

It has been identified by the authors that there are three errors in this paper.

Table 4: Criteria listed under subheading ‘Definitions for measurable disease’ should also include:

‘Bone marrow plasma cells $\geq 30\%$.’

Table 5: Bone marrow criteria for CR should be ‘<5% plasma cells’ and not ‘ $\leq 5\%$ plasma cells’.

Table 6: Relapse criteria for progressive disease should state ‘Increase of $\geq 25\%$ from lowest response level’ and not ‘Increase of $\geq 25\%$ from baseline’.

The authors apologize for these errors.

Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia

NI Noguera, E Ammatuna, D Zangrilli, S Lavorgna, M Divona, F Buccisano, S Amadori, C Mecucci, B Falini and F Lo-Coco

Leukemia (2007) 21, 1134. doi:10.1038/sj.leu.2404664

Correction to: *Leukemia* (2005) 19, 1479–1482.

doi:10.1038/sj.leu.2403846

It has been identified by the authors that there is an error in the sequence of primers used for FLT3 amplification (Table 1).

The correct sequence is as follows:

The authors apologize for any inconvenience caused.

Table 1

Name	Sequence	Dye	Position	Accession number	PCR (product size)
(D3)ITD-R6	5'-atcctagtagcttcccaaac-3'	D3	1913–1934	NM_004119	Flt3-ITD (366 bp)
R5-ITD	5'-tgtcgagcagtagctctaaaca-3'		1569–1589	NM_004119	